GLP-1 Family advanced
GLP-1 Agonist Cardiovascular Protection
Evidence for cardiovascular benefits of GLP-1 receptor agonists including reduced MACE and heart failure hospitalizations.
By Encyclopeptide Editorial | 1 min read
GLP-1 cardiovascular CVOT MACE heart-failure
Key Cardiovascular Outcome Trials
LEADER (Liraglutide)
- HR for MACE: 0.87 (95% CI 0.78-0.97)
- CV death: 0.78 (95% CI 0.66-0.93)
SUSTAIN-6 (Semaglutide SC)
- HR for MACE: 0.74 (95% CI 0.58-0.95)
SELECT (Semaglutide - Obesity)
- HR for MACE: 0.80 (95% CI 0.72-0.90)
REWIND (Dulaglutide)
- HR for MACE: 0.88 (95% CI 0.79-0.99)
Mechanisms of CV Protection
- Anti-inflammatory effects
- Improved endothelial function
- Plaque stabilization
- Weight loss and improved lipid profiles
Chemical Identity
| Property | Value |
|---|---|
| Name | GLP-1 Agonist Cardiovascular Protection |
| Category | GLP-1 Family |
References
- Encyclopeptide Database. “GLP-1 Agonist Cardiovascular Protection” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about GLP-1 Agonist Cardiovascular Protection with interactive quizzes on Wikipept.
Take a Quiz on Wikipept